Fairfield, Bush & Co’s GSK GSK Stock Holding History

Fairfield, Bush & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-473	Closed	-$17.5K	–	253
2023 Q4	$17.5K	Buy	+473	New	+$17K	0.01%	260
2023 Q3	–	Sell	-773	Closed	-$27.6K	–	263
2023 Q2	$27.6K	Buy	+773	New	+$27.7K	0.01%	250
2022 Q3	–	Sell	-1,475	Closed	-$80K	–	249
2022 Q2	$80K	Buy	+1,475	New	+$81.4K	0.05%	165
2016 Q4	–	Sell	-3,810	Closed	-$205K	–	149
2016 Q3	$205K	Sell	3,810 -480	-11%	-$26.3K	0.07%	143
2016 Q2	$232K	Sell	4,290 -460	-10%	-$24.2K	0.08%	123
2016 Q1	$241K	Hold	4,750	–	–	0.09%	119
2015 Q4	$240K	Sell	4,750 -1,360	-22%	-$69.3K	0.08%	131
2015 Q3	$294K	Sell	6,110 -400	-6%	-$20.8K	0.13%	103
2015 Q2	$339K	Hold	6,510	–	–	0.1%	130
2015 Q1	$376K	Hold	6,510	–	–	0.11%	130
2014 Q4	$348K	Hold	6,510	–	–	0.1%	131
2014 Q3	$374K	Hold	6,510	–	–	0.11%	127
2014 Q2	$435K	Buy	6,510 +1,760	+37%	+$119K	0.13%	114
2014 Q1	$317K	Hold	4,750	–	–	0.15%	82
2013 Q4	$317K	Hold	4,750	–	–	0.14%	85
2013 Q3	$297K	Hold	4,750	–	–	0.09%	125
2013 Q2	$297K	Buy	+4,750	New	+$301K	0.15%	109

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fairfield, Bush & Co's GSK Position: Q1 2024 in Review

Fairfield, Bush & Co sold out of GSK (GSK) in Q1 2024, closing a stake of 473 shares — an estimated $17.5K sold.

Fairfield, Bush & Co first reported a position in GSK in Q2 2013 and held it in 17 quarters. The position peaked at $435K in Q2 2014. 910 funds tracked by Wall St. Rank hold GSK as of Q1 2024.

Fairfield, Bush & Co reported no remaining GSK position as of Q1 2024 after selling out during the quarter.
Fairfield, Bush & Co sold 473 GSK shares in Q1 2024, an estimated $17.5K.
Fairfield, Bush & Co first reported a position in GSK in Q2 2013 and held it in 17 quarters.
Fairfield, Bush & Co's GSK position peaked at $435K in Q2 2014.
910 funds tracked by Wall St. Rank held GSK as of Q1 2024.

Based on Fairfield, Bush & Co's 13F filing for Q1 2024, filed 15 May 2024.